Definitive Contract 75N95018C00042
Award Date
9/24/18
Potential Completion Date
11/12/18
Potential Value
$903K
Federal Agency
National Institute on Drug Abuse
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
NAICS Category
334516 - Analytical Laboratory Instrument Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $513,896.40 firm fixed price delivery order contract to Illumina, Inc. to provide sequencing and array-based genomic analysis solutions. Illumina, a for-profit manufacturer, will deliver a range of sequencing systems, reagents, consumables, and bioinformatics products to support the agency's research and diagnostic needs. This order is part of Illumina's existing Indefinite...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a firm fixed price delivery order contract to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $250,675.20 award, with a completion date of March 8, 2018, is for the provision of sequencing systems, reagents, consumables, and associated services to support the agency's genomics research and diagnostics efforts. Illumina has...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a firm fixed price delivery order contract to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The $290,432.92 contract does not have a set-aside designation and was awarded on September 14, 2018 with a completion date of September 2, 2020. Illumina, a for-profit organization, has previously provided sequencing systems, reagents, and services to support...
This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Illumina, Inc. The $292,500.00 contract is for the provision of Illumina sequencing systems, reagents, and associated products and services to support genomic sequencing and analysis. Illumina is an experienced provider of sequencing and genomic analysis technologies to federal agencies, having previously supported work at the NIH, Centers for...
The U.S. National Institute on Drug Abuse (NIDA), a civilian agency of the federal government, awarded a firm fixed-price purchase order contract to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions. The $8,003.02 contract is for the delivery of a cluster kit and two sequencing kits using Illumina's proprietary technology. This award is not associated with a set-aside program. Illumina has previously secured other prime federal contracts and sub-awards...
The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a firm-fixed-price delivery order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents. The $451,656.00 contract does not include any set-aside designation. The award supports the provision of Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as associated reagents, consumables, sample preparation kits,...
This is a firm fixed price delivery order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract, valued at $1,897,352.58, does not have a set-aside designation. Illumina will provide various NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as accompanying reagents, consumables, sample prep kits, sequencing chips,...
This is a firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Illumina, Inc. The $252,500.00 contract is for the provision of Illumina's genetic sequencing systems, reagents, and associated services. This contract does not have a set-aside designation. Illumina is a manufacturer of genetic analysis instruments and reagents, and has previously been awarded both prime federal contracts and...
This is a firm fixed-price delivery order awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Illumina, Inc. The $96,908.57 contract is for the provision of various Illumina sequencing systems, reagents, and related services to support genomic sequencing and analysis research. This appears to be a task order under a larger Indefinite Delivery Contract (IDC) that Illumina holds with the Department of the Navy Bureau of Medicine and...
The Department of Health and Human Services National Institutes of Health National Institute of Environmental Health Sciences awarded a firm fixed price delivery order contract to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $161,111.01 contract has a completion date of September 2, 2025 and does not include a set-aside designation. Illumina has previously provided a range of sequencing instruments, reagents, and bioinformatics...